Mesenchymal stem cells promote erlotinib resistance in non-small cell lung cancer through the HGF-AKT/ERK1/2-OPN pathway
Yue Yang, Jianxin He, Feng Long, Yongqi Liu, Lin Li, Hulai Wei
Northwest Minzu University State Ethnic Affairs Commission Lanzhou University Gansu University of Traditional Chinese Medicine
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Objectives: To investigate the mechanisms by which mesenchymal stem cells (MSCs) contribute to erlotinib resistance in non-small cell lung cancer (NSCLC).Methods: HCC827 NSCLC cells were treated with MSC-conditioned medium (MSC-CM).Cell viability and apoptosis were evaluated using MTT assays and flow cytometry, respectively.Protein and mRNA expression levels were assessed by western blotting and quantitative real-time PCR.For in vivo validation, a xenograft model was established by co-injecting HCC827 cells and MSCs into NOD/SCID mice.Results: MSC-CM significantly increased cell viability and reduced apoptosis in HCC827 cells following erlotinib treatment, indicating enhanced drug resistance.Mechanistically, MSC-secreted hepatocyte growth factor (HGF) activated AKT and ERK1/2 phosphorylation, thereby bypassing EGFR inhibition by erlotinib.Neutralization of HGF restored erlotinib sensitivity in MSC-CM-treated HCC827 cells.Furthermore, osteopontin (OPN) was transcriptionally upregulated and acted as a resistance enhancer.Inhibition of OPN attenuated MSC-CM-mediated resistance.In vivo, tumors derived from co-injected MSCs and HCC827 cells exhibited significantly greater volume and weight after erlotinib treatment compared to control tumors.Conclusions: This study identifies a novel MSC-mediated resistance mechanism in which MSC-derived HGF activates compensatory AKT/ERK1/2 signaling, circumventing EGFR blockade by erlotinib.Concurrent upregulation of OPN in NSCLC cells forms a synergistic survival axis under erlotinib pressure.These findings suggest that targeting MSC-derived HGF and tumor-derived OPN may offer promising strategies to overcome erlotinib resistance in NSCLC.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Lung Cancer Treatments and Mutations
Cancer Cells and Metastasis · Mesenchymal stem cell research